| abstract |
The invention relates to a method for determining the probability of a metastasis developing in a cancer patient, as well as a method for designing a personalised therapy for a cancer patient, in particular a patient with breast cancer, colon cancer, lung cancer, kidney cancer or thyroid cancer, based on determining the expression level of one or more genes of which the expression is modulated by an increase in the expression of c-MAF. The invention also relates to a method for identifying marker genes that identify a predisposition to cancer metastasis based on the induction of the modulation of the expression of c-MAF'. The invention further relates to the use of PTHLH and PODXL inhibiting agents and to RERG activating agents in the treatment and/or prevention of the metastasis of a cancer, particularly breast cancer, colon cancer, lung cancer, kidney cancer or thyroid cancer. |